- Home
- SVRN vs LSTA Comparison
SVRN vs LSTA Comparison
Compare SVRN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | LSTA |
|---|---|---|
| Founded | 2021 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 15.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SVRN | LSTA |
|---|---|---|
| Price | $34.16 | $1.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 151.8K | 78.9K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.16 | $0.96 |
| 52 Week High | $74.74 | $5.07 |
Technical Indicators
Market Signals| Indicator | SVRN | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 34.39 |
| Support Level | $4.53 | $0.99 |
| Resistance Level | $52.00 | $1.28 |
| Average True Range (ATR) | 7.07 | 0.10 |
| MACD | -2.05 | -0.00 |
| Stochastic Oscillator | 40.58 | 11.02 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.